Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • VX-765: Selective Caspase-1 Inhibitor for Inflammation Re...

    2026-03-30

    VX-765: Selective Caspase-1 Inhibitor for Inflammation Research

    Executive Summary: VX-765 is a highly selective, orally bioavailable inhibitor of caspase-1, critical for research on inflammasome-driven inflammation and pyroptosis (APExBIO). The compound suppresses the release of key pro-inflammatory cytokines, interleukin-1β (IL-1β) and IL-18, without affecting unrelated cytokines such as TNFα and IL-6 (Israelov et al. 2020). Preclinical studies have shown VX-765 significantly reduces inflammatory injury in mouse models of rheumatoid arthritis, skin inflammation, and blood-brain barrier (BBB) disruption. VX-765's active metabolite, VRT-043198, is responsible for its potent caspase-1 inhibition and downstream effects. The compound's specificity, stability, and well-defined workflow parameters make it a benchmark tool for translational inflammation research and targeted cytokine modulation (see related article).

    Biological Rationale

    Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease that processes pro-IL-1β and pro-IL-18 into their active, secreted forms (Israelov et al. 2020). The activation of caspase-1 is central to the assembly and function of the inflammasome complex, a key driver in many acute and chronic inflammatory states. Unchecked caspase-1 activity leads to excessive cytokine release and pyroptosis, a lytic and inflammatory form of programmed cell death particularly relevant in macrophages and endothelial cells. This pathway is implicated in autoimmune diseases (e.g., rheumatoid arthritis), neuroinflammation, skin disorders, and infectious diseases such as HIV (mechanism-focused review). Targeted inhibition of caspase-1 enables researchers to specifically dissect the role of IL-1β/IL-18 signaling and pyroptosis, distinguishing these processes from other caspase-dependent pathways (e.g., apoptosis via caspase-8/9).

    Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

    VX-765 is a prodrug that is rapidly converted in vivo into its active metabolite, VRT-043198 (APExBIO). VRT-043198 selectively and reversibly inhibits caspase-1 by targeting the enzyme's active site, blocking the proteolytic maturation of pro-IL-1β and pro-IL-18, thereby preventing their secretion (Israelov et al. 2020). This mechanism does not affect other cytokines such as IL-6, TNFα, or IL-8, nor does it inhibit apoptosis-related caspases at standard concentrations (-10 μM in cell assays). In animal models, oral administration of VX-765 (typically 25-100 mg/kg) results in dose-dependent reduction of caspase-1 activity and cytokine release, with pharmacokinetic studies confirming high oral bioavailability and rapid systemic conversion to VRT-043198 (see translational review). The selectivity of VX-765 for the ICE/caspase-1 subfamily underpins its utility in teasing apart inflammasome-specific signaling from broader caspase networks.

    Evidence & Benchmarks

    • VX-765 robustly inhibits caspase-1 activity and reduces IL-1β and IL-18 secretion in vitro and in vivo models of blood-brain barrier injury (Israelov et al. 2020).
    • Oral VX-765 treatment (25-100 mg/kg, daily, 5 days) significantly decreases PBMC adhesion, transmigration, and restores VE-cadherin levels in paraoxon-induced BBB injury models (Israelov et al. 2020).
    • In rheumatoid arthritis mouse models, VX-765 reduces joint inflammation and cytokine levels in a dose-dependent manner (see product data).
    • In HIV-infected lymphoid tissues, VX-765 prevents CD4 T-cell pyroptosis without impairing non-pyroptotic cell viability (mechanistic review).
    • VX-765 does not significantly inhibit caspase-8, caspase-9, or other apoptosis executioner caspases at concentrations effective for caspase-1 inhibition (Israelov et al. 2020).

    This article extends prior coverage by providing updated in vivo BBB injury data and explicit workflow parameters for translational research. For a mechanistic deep-dive, see the mechanism-focused review; this article clarifies distinctions between inflammasome-dependent and independent outcomes. For translational perspectives, this review presents VX-765 as the gold standard, while here, we document limitations and best practices.

    Applications, Limits & Misconceptions

    VX-765 is widely used in:

    • Biochemical caspase-1 activity assays using substrates such as suc-YVAD-p-nitroanilide.
    • Cellular studies of inflammasome activation, cytokine secretion, and pyroptosis (especially in macrophages and endothelial cells).
    • Preclinical models of diseases with prominent inflammasome activation, including rheumatoid arthritis, skin inflammation, and CNS injury (Israelov et al. 2020).
    • HIV research to prevent CD4 T-cell death via pyroptosis inhibition.

    Common Pitfalls or Misconceptions

    • VX-765 does not inhibit apoptosis induced by caspase-8/9 or executioner caspases at recommended doses; its effects are specific to caspase-1 and related ICE-like proteases.
    • It is insoluble in water; use DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic assistance) for stock solutions (APExBIO).
    • Solutions are not stable for long-term storage; prepare freshly for each experiment and store desiccated at −20°C.
    • Anti-inflammatory effects are limited to IL-1β/IL-18 pathways; VX-765 does not suppress TNFα, IL-6, or IL-8 release.
    • Translational effects in animal models may not fully predict human therapeutic outcomes; VX-765 is for research use only.

    Workflow Integration & Parameters

    For in vitro assays, VX-765 is typically used at 1–10 μM in media containing ≤0.1% DMSO. For animal studies, oral dosing ranges from 25–100 mg/kg/day for 5–10 days, depending on the inflammatory model. The compound should be dissolved in DMSO or ethanol, diluted appropriately, and administered via oral gavage or included in diet. Caspase-1 activity is usually measured using chromogenic or fluorogenic substrates (e.g., YVAD-pNA). Cytokine release is quantified by ELISA or multiplex bead assays. APExBIO (SKU: A8238) supplies VX-765 as a solid for research use (product page).

    Conclusion & Outlook

    VX-765 remains the benchmark selective caspase-1 inhibitor for inflammation and pyroptosis research, enabling precise dissection of IL-1β/IL-18 signaling and cell death in preclinical models. Its oral bioavailability, metabolic stability, and robust selectivity profile support its use across diverse disease models. While translational promise is strong, researchers must consider its specificity and appropriate experimental controls. For additional insights into advanced strategies and translational workflows, see this application-focused review, which builds on the mechanistic and workflow details presented here. VX-765, provided by APExBIO, continues to support innovation in the study of inflammasome biology and anti-inflammatory drug development.